Related Experiment Videos
Myeloperoxidase biosynthesis by a human promyelocytic leukemia cell line: insight into myeloperoxidase deficiency
Abstract:
The biosynthesis and processing of myeloperoxidase (MPO), a cationic enzyme present in the azurophilic granules of human polymorphonuclear leukocytes (PMNs), were studied in the human promyelocytic leukemia cell line, HL-60. HL-60 cells produce large quantities of enzymatically active MPO that has the same electrophoretic behavior as MPO isolated from normal PMNs. Mature MPO is a glycoprotein of approximately 150,000 molecular weight (mol wt) composed of two heavy-light protomers (alpha 2 beta 2) with subunits of 59,000 and 13,500 mol wt, respectively, under reducing conditions. The primary translation product of MPO messenger RNA (mRNA) isolated from HL-60 cells was a single polypeptide of mol wt 80,000. In HL-60 cells labeled with [35S]-methionine, the labeled MPO isolated by immunoprecipitation had a mol wt of 89,000. Treatment of this 89-kilodalton (kDa) species with endoglycosidase H produced a 79-kDa peptide, suggesting that the 89-kDa protein contained high-mannose side chains. The 89-kDa species had no detectable peroxidase activity. During chase experiments some of the 89-kDa peptide was processed to smaller species of mol wt 39,000, 59,000, and 13,500, although a fraction of the 89-kDa peptide remained unprocessed after a chase of 100 hours. In addition, a small amount of the 89-kDa peptide appeared in the medium without any of the processed smaller peptides. These studies suggest that the primary translation product in MPO biosynthesis is an 80-kDa peptide that undergoes cotranslational cleavage of the signal peptide and glycosylation to produce an 89-kDa pro-MPO, that pro-MPO is a single polypeptide containing the alpha and beta subunits of MPO and contains endoglycosidase H-susceptible high-mannose side chains, and that posttranslational modification of pro-MPO results in targeting to the lysosome and proteolytic maturation of pro-MPO to active enzyme. In light of the previous observation that MPO-deficient and normal PMNs contain an 89-kDa protein immunochemically related to MPO, these studies on MPO biosynthesis indirectly support the hypothesis that defective posttranslation processing by pro-MPO may underlie hereditary MPO deficiency.
Insights
Myeloperoxidase (MPO) biosynthesis begins with an 80-kDa peptide that is glycosylated into an 89-kDa pro-MPO. Post-translational processing is crucial for generating active MPO and may be impaired in hereditary MPO deficiency.
Area of Science:
- Biochemistry
- Cell Biology
- Immunology
Background:
- Myeloperoxidase (MPO) is a key enzyme in human polymorphonuclear leukocytes (PMNs), crucial for innate immunity.
- Understanding MPO biosynthesis and processing is vital for elucidating its function and associated deficiencies.
Purpose of the Study:
- To investigate the biosynthesis and post-translational processing of MPO in the HL-60 cell line.
- To identify the primary translation product and intermediate forms of MPO.
- To explore the potential mechanisms underlying hereditary MPO deficiency.
Main Methods:
- Utilized the HL-60 human promyelocytic leukemia cell line.
- Employed [35S]-methionine labeling and immunoprecipitation to track MPO synthesis.
- Applied endoglycosidase H treatment to analyze glycosylation.
- Conducted chase experiments to study MPO processing over time.
Main Results:
- Identified an 80-kDa primary translation product of MPO mRNA.
- Characterized an 89-kDa glycosylated pro-MPO intermediate with endoglycosidase H-sensitive high-mannose side chains.
- Observed limited processing of pro-MPO to smaller subunits (39, 46, and 13.5 kDa) and active MPO.
- Detected unprocessed pro-MPO and secreted forms, suggesting inefficient maturation.
Conclusions:
- MPO biosynthesis involves an 80-kDa precursor that is converted to an 89-kDa pro-MPO via signal peptide cleavage and glycosylation.
- Post-translational modification and proteolytic cleavage are essential for generating active MPO.
- Defective post-translational processing of pro-MPO may underlie hereditary MPO deficiency.